The pharmaceutical industry in China is on a rising curve
and is leading on the international platform. The Chinese health sector has
grown to a robust industry of $357 billion at present and is poised to grow to
$1 trillion in 2020. It covers a wide range of synthetic chemicals, drugs,
medical devices, instruments, hygiene materials, packing materials and
pharmaceutical industry. Research and development has increased swiftly and
foreign health institutions and companies have captured 20% of its overall sales.
Three key factors that shape the market of healthcare
industry in China are the continuation of economic and demographic trends;
policies implemented by the Chinese government’s 12th five year plan
and advanced healthcare reforms. Continuing urbanization and income growth have
also contributed to its growth. This positive picture implies that the
government is now more focused on healthcare as a social responsibility.
Healthcare expenditures in China have doubled and form almost 5% of the
country’s GDP. Both the traditional and the pharmaceutical companies in China
have benefitted in the recent years.
Multinational companies show huge interest in China’s
pharmaceutical market today due to effective healthcare reforms, the
government’s commitment to constant innovation and several tax incentives. Various
multinational health firms are setting up research and development centres in
China. The manufacturing organizations
in China have successfully met the international standard in the quality of
their pharma products thus attracting more international investment.
No comments:
Post a Comment